Tesamorelin and Ipamorelin are two peptides combined in a blend that seems to be sharing the potential to stimulate the growth hormone axis, although through different mechanisms. This combination might activate the pituitary gland, which further results in the release of endogenous growth hormone. The blend seems to be showing positive effects on mammals and primates in terms of sleep, lipid profile, mean mass, muscle tissues, cognition, and metabolic function.

Chemical Structure

Molecular Formula

• Tesamorelin: C221H366N72O67S
• Ipamorelin: C38H49N9O5

Molecular Weight

• Tesamorelin: 5136 g/mol
• Ipamorelin: 711.9 g/mol

Sequence

• Tesamorelin: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
• Ipamorelin: H-Aib-His-D-2Nal-D-Phe-Lys-NH2

Tesamorelin and Ipamorelin Blend – GH Deficiency

Tesamorelin is an analog of the growth hormone-releasing hormone. It binds GHRG receptors on somatotrophs in the pituitary gland. Considering that it promotes the release of GH, Tesamorelin could boost lipolysis, reduce visceral adipose tissue, and potentially improve glucose metabolism.

Ipamorelin is a GHSR antagonist as well. However, it appears to be activating GHSR in the peripheral tissues and hypothalamus, potentially causing the release of GH. Researchers suggest that since GHSR stimulates the increase of GH secretion, it can promote lipolysis, protein synthesis, and IGF-1 production.

When combined, these two compounds target different components of the GH axis. This dual action seems to positively affect and amplify the overall GH, like insulin sensitivity, lipid profile, body composition, and overall metabolic function in a laboratory setting.

Tesamorelin and Ipamorelin Blend and Type 2 Diabetes

Research has shown that both Tesamorelin and Ipamorelin may help manage blood sugar levels and address metabolic issues in people with Type 2 Diabetes (T2DM). Tesamorelin works by boosting the body’s own production of growth hormone, which experts believe improves how the body responds to insulin and uses glucose. On the other hand, studies on Ipamorelin suggest it may positively affect insulin sensitivity and glucose regulation. When used together, these peptides could offer combined benefits, potentially leading to lower HbA1c levels, better insulin sensitivity, and reduced abdominal fat with T2DM.

Other benefits

• In animal models, this blend seems to have a positive effect on the following:
• Cognitive improvement – may improve memory and learning abilities.
• Muscle density – might enhance muscle density and size.
• Appetite and digestion – according to one research, animals that were given this blend managed to decrease their weight by 15%.

References:

Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405.

Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. PMID: 28617838; PMCID: PMC5472315.

https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin#section=Deprecated-CAS

Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486.

https://www.sciencedirect.com/science/article/abs/pii/S1096637401902394?via%3Dihub